Every material Form 8-K GENELUX Corp has filed with the SEC since January 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Genelux entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that lets the company sell up to $100 million of common stock from time to time through TD Cowen as sales agent or principal. The company is not obligated to sell any shares and may suspend sales at any time, and it plans to use any proceeds for general corporate purposes, including research and development and clinical trial expenses.
Aggregate offering price of up to $100 million of common stock, par value $0.001 per share
TD Cowen compensation of up to 3.0% of gross proceeds from any shares sold, plus certain offering expenses
Sales are made under Form S-3 registration statement (File No. 333-276847), effective February 13, 2024, with a prospectus supplement to be filed March 19, 2026
Company is not required to sell any shares and may suspend sales at any time
Genelux Corporation updated its corporate presentation on February 2, 2026, with what it describes as certain business and strategic updates. The filing is a routine furnishing of investor materials, and the filing itself does not state specific financial figures or new guidance.
Corporate presentation updated February 2, 2026, and posted to the Investors section of investors.genelux.com
Presentation furnished as Exhibit 99.1 under Regulation FD and not deemed filed under Section 18 of the Exchange Act
Filing does not include financial results, guidance, or the specific content of the strategic updates in the body text
Genelux Corporation agreed on January 8, 2026 to sell 6,666,667 new shares of common stock at $3.00 per share through an underwritten offering led by Lucid Capital Markets, expected to bring in about $20.0 million gross before underwriting discounts and expenses. The company says net proceeds will go to general corporate purposes, including research and development and clinical trial costs, and the new shares will dilute existing holders' ownership.
Offering of 6,666,667 shares at $3.00 per share, with gross proceeds of about $20.0 million before discounts and expenses
Underwriter has a 30-day option to buy up to 1,000,000 additional shares at the offering price
Closing is expected on or about January 9, 2026, subject to customary closing conditions
Proceeds are expected to fund general corporate purposes, including research and development and clinical trial expenses
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GENELUX Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →